1 |
Asselin-Labat M-L, Vaillant F, Sheridan JM, et al (2010). Control of mammary stem cell function by steroid hormone signalling. Nature, 465, 798-802.
DOI
ScienceOn
|
2 |
Azria D, Larbouret C, Cunat S, et al (2005). Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res, 7, 156-63.
DOI
ScienceOn
|
3 |
Bai Z, Gus R (2009). Breast cancer, estrogen receptor and ligands. Arch Pharm Chem Life Sci, 342, 133-49.
DOI
ScienceOn
|
4 |
Baum M (1999). Use of aromatase inhibitors in the adjuvant treatment of breast cancer. Endocrine-Related Cancer, 6, 231-4.
DOI
ScienceOn
|
5 |
Baum M, Buzdar AU, Cuzick J, et al (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet, 359, 2131-9.
DOI
ScienceOn
|
6 |
Bedi KS, Goldstein DJ (1976). apparent anomalies in nuclear feulgen-DNA contents. J Cell Bio, 71, 68-88.
DOI
ScienceOn
|
7 |
Buzdar AU (2003). Advances in endocrine treatments for postmenopeusal women with metastatic and early breast cancer. Oncologist, 8, 335-41.
DOI
ScienceOn
|
8 |
Campos SM (2004). Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist, 9, 126-36.
DOI
ScienceOn
|
9 |
Cetin I, Topcul M (2012). Cancer stem cells in oncology. J BUON, 17, 644-8.
|
10 |
Davies C, Godwin J, Gray R, et al (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378, 771-84.
DOI
ScienceOn
|
11 |
Dowsett M, Smith IE, Ebbs SR, et al (2005). Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res, 11, 951-8.
|
12 |
Gruvberger S, Ringner M, Chen Y, et al (2001). Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res, 61, 5979-84.
|
13 |
Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov, 2, 205-13.
DOI
ScienceOn
|
14 |
Kjellstrand P (1980). Mechanisms of the feulgen acid hydrolysis. J Microscopy, 119, 391-6.
DOI
ScienceOn
|
15 |
Klotz IM (1982). Numbers of receptor sites from Scatchard graphs: facts and fantasies. Science, 217, 1247-9.
DOI
|
16 |
Long BJ, Jelovac D, Handratta V, et al (2004). Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J National Cancer Institute, 96, 456-65.
DOI
ScienceOn
|
17 |
McGuire WL, Tandon AK, Allred DC, Chamness GC, McClark GM (1990). How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst, 82, 1006-15.
DOI
|
18 |
Mouridsen H, Gershanovich M, Sun Y, et al (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol, 21, 2101-9.
DOI
ScienceOn
|
19 |
O'Neill M, Paulin FEM, Vendrell J, Ali CW, Thompson AM (2012). The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model. BioDiscovery, 6, 1-8.
|
20 |
Mouridsen HT (2007). Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat, 105, 19-29.
DOI
|
21 |
Osborne CK (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med, 339, 1609.
DOI
ScienceOn
|
22 |
Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P (2008). Aromatase inhibitors for breast cancer: different structures, same effects? Endocr Relat Cancer, 15, 27-36.
DOI
ScienceOn
|
23 |
Santen RJ, Harvey HA (1999). Use of aromatase inhibitors in breast carcinoma. Endocrine-Related Cancers, 6, 75-92.
DOI
ScienceOn
|